Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Sees Significant Increase in Short Interest

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the recipient of a significant increase in short interest in February. As of February 13th, there was short interest totaling 181,710 shares, an increase of 26.1% from the January 29th total of 144,124 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average trading volume of 91,000 shares, the short-interest ratio is currently 2.0 days. Based on an average trading volume of 91,000 shares, the short-interest ratio is currently 2.0 days. Approximately 1.3% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Kairos Pharma in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kairos Pharma currently has an average rating of “Buy” and a consensus price target of $8.33.

Hedge Funds Weigh In On Kairos Pharma

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in shares of Kairos Pharma during the 2nd quarter valued at about $44,000. Two Sigma Investments LP purchased a new stake in Kairos Pharma in the third quarter valued at approximately $54,000. Finally, FNY Investment Advisers LLC bought a new stake in Kairos Pharma during the third quarter valued at approximately $27,000.

Kairos Pharma Price Performance

NYSEAMERICAN KAPA opened at $0.61 on Tuesday. The company’s 50 day simple moving average is $0.71 and its two-hundred day simple moving average is $0.96. The stock has a market capitalization of $12.70 million, a PE ratio of -1.97 and a beta of 2.28. Kairos Pharma has a 1 year low of $0.40 and a 1 year high of $2.11.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.